Monthly Archives: June 2013

June 7 2013 – Genoa, McMaster University reveal findings of GP-101 in pulmonary fibrosis treatment

US-based inhaled medicines provider Genoa Pharmaceuticals in collaboration with McMaster University has demonstrated advantages of the inhaled aerosol pirfenidone (GP-101) in the treatment of pulmonary fibrosis. The findings showed that small inhaled doses yielding high peak, short duration lung pirfenidone … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , | Leave a comment

May 24 2013 – Reflux Medicine Boosts Survival in Lung Disease

PHILADELPHIA  —  Survival in idiopathic pulmonary fibrosis (IPF) improved significantly in patients treated with proton pump inhibitors (PPIs), adding to a body of literature supporting PPI benefits in IPF, investigators in a retrospective review concluded. Patients treated with PPIs had … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 22 2013 – Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., May 22, 2013 —Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, unveiled data from a clinical study of PRM-151 in an oral presentation at the 2013 American Thoracic Society (ATS) … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

May 21 2013 – Genetic variation among patients with pulmonary fibrosis associated with improved survival

Variation in the gene MUC5B among patients with idiopathic pulmonary fibrosis was associated with improved survival, according to a study published online by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

May 21 2013 – Race Horses May Hold Key to Cure for Deadly Lung Disease Killing Humans, Horses, Other Domestic Animals

LOUISVILLE, Ky., May 20, 2013 /PRNewswire-USNewswire/ — Researchers from human and veterinary medicine want to know more about the lung disease that is killing horses, including thoroughbred horses and other domestic animals, just as it’s claiming an increasing number of … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 16 2013 – Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting

LEXINGTON, Mass.–(BUSINESS WIRE)–May 16, 2013– Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 8 2013 US/EU – Idiopathic pulmonary fibrosis drug sales “to rise 86.6%/year to 2017″

The idiopathic pulmonary fibrosis (IPF) therapy market across the US and European Union (EU) will be worth more than $1.1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 6 2013 – Ambrisentan Fails in Lung Fibrosis

The pulmonary hypertension drug ambrisentan (Letairis) was supposed to tackle one of the root causes of idiopathic pulmonary fibrosis but actually worsened that disease, the ARTEMIS-IPF clinical trial showed. In relatively mild IPF patients, ambrisentan appeared to accelerate disease progression … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

April 29 2013 – Interventions to Improve Symptoms, Quality of Life in Fibrotic ILD: Do They Work?

Patients with fibrotic interstitial lung diseases (e.g. idiopathic pulmonary fibrosis) have a poor overall prognosis, and there are no therapies proven to halt disease progression or extend life. Further, many of these patients have debilitating symptoms, limited functional capacity, and … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , | Leave a comment

April 17 2013 – Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , | Leave a comment